There are a huge number of reasons to invest in stem cell market intelligence, including that it will:
- Position yourself to knowledgeably approach investors – Without a doubt, investors will ask you for data on market size, market share, and market leaders.
- Target high-value opportunities – You need trend data to know where to focus your company’s time and resources.
- Increase sales from stem cell products – The fastest way to increase product sales is better understand the needs of your clients (that’s why we survey your end-users).
- Decrease risks associated with new product development – You don’t want to develop products that the market does not want or cannot support.
However, the single most important purpose of stem cell market intelligence is to make smarter decisions, faster.
I believe that you deserve to make informed, profitable decisions, while freeing yourself up to focus on more urgent issues that need your attention.
That is why BioInformant has spent the past decade (2006 to present) tracking the stem cell industry for you. We use continuously maintained dashboards, combined with systems that trigger alerts when stem cell industry trends exhibit unexpected variation.
BioInformant’s Stem Cell Industry Reports
Four of BioInformant’s top-selling stem cell market intelligence reports are highlighted below.
This 204-page global strategic report reveals key metrics impacting the cord blood banking industry, including rates of clinical trials, scientific publications, grants, patents, product launches, new market entrants, and more. It analyzes strategic partnerships, deal-making within the industry, and investments flowing into the industry, including contributions from ABS Capital Partners, KKR & Company, Bay City Capital, GTCR LLC, and Excalibur. In addition to analyzing opportunities for storage of cord blood and cord tissue products, it considers opportunities for storage of other perinatal stem cell types (placental, amniotic, and more). Importantly, it includes a 40-question, 52-page survey completed by 600+ recent and expectant parents that reveals how to effectively educate parents, prioritize your marketing budget, and understand why parents bank publicly, privately, or not at all. Access to these market insights are vital, because the cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.
This global strategic report evaluates opportunities from across the stem cell product spectrum. It tracks traditional market metrics, which include trend rate data for stem cell clinical trials, scientific publications, grants, patents, product launches, new market entrants, acquisitions, and more. However, it also tracks social analytics, which are metrics derived from social media sites, search engines, and online advertising platforms. The significance of social analytics is that they reveal individual user behavior on a topic, as well as aggregate group activity. Importantly, they allow you to identify the frequency at which online users are searching for, posting about, and seeking out stem cell product information. Another distinctive feature of this report is an end-user survey of 289 researchers worldwide that identify stem cells as their core research focus. These survey findings reveal functional needs, technical preferences, and key factors influencing buying decisions among stem cell researchers.
To date, more than 30,000 scientific publications have been published about mesenchymal stem cells (MSCs) and the number released per year has increased for 26 years straight. There are also nearly 500 active MSC clinical trials underway worldwide. Importantly, this global report tracks traditional market metrics, which include trend rate data for MSC clinical trials, scientific publications, grants, patents, product launches, new market entrants, acquisitions, and more. However, it also tracks new social analytics, which are metrics derived from social media sites, search engines, and online advertising platforms. Social analytics identify that MSCs are more frequently cited than any other stem cell type and Google Trend data reveals MSC searches to be nearly twice as common as the next most popular stem cell type. Claim access to these insider insights to optimally position yourself within the MSC marketplace.
Since the discovery of iPSCs, a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. Today, the number of iPSC products sold worldwide is increasing with double-digit growth. In addition, 22% of stem cell researchers now report using iPSCs within a research project. A distinctive feature of this report is an end-user survey of 273 researchers (131 U.S. / 143 International) that identify having iPSCs as a research focus. These survey findings reveal functional needs, technical preferences, and key factors influencing buying decisions among iPSC researchers. With Cynata Therapeutics announcing news this weekthat it is positioned to launch the world’s first clinical trial involving an allogeneic iPSC-derived product, you need to be well-informed about opportunities and risks within the global iPSC marketplace.
BioInformant.com is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving industry leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.